serotyped by Neufeld's Quellung reaction using type and factor sera provided by the Statens Serum Institut, Copenhagen, Denmark. Multilocus sequence typing (MLST) of the telithromycin-resistant isolate was carried out as described previously (3) .
Pneumococcal strains were isolated from the following sources: blood (n ϭ 137 [28.2%]), bronchoalveolar lavage (n ϭ 34 [7. 0%]), cerebrospinal fluid (n ϭ 6 [1.2%]), sinus swab and puncture (n ϭ 79 [16.3%] ), sputum (n ϭ 139 [28.6%]), tracheal secretion (n ϭ 47 [9.7%]), and other respiratory tract sources (n ϭ 44 [9.1%] ). Antimicrobial susceptibility data of the isolates are presented in Table 1 . Upon examination, 7.2% of isolates were found to be penicillin G intermediate, and only one isolate was resistant to penicillin G (MIC Ն 2 g/ml). Ninety-two (18.9%) and 27 (5.6%) isolates were resistant to erythromycin A and clindamycin, respectively. Only one isolate was found to be levofloxacin resistant.
Erythromycin A-nonsusceptible isolates (n ϭ 93) were analyzed to determine their underlying resistance determinants. Of these, 65 (69.9%) and 28 (30.1%) belonged to the mef(A) and erm(B) types of resistance, respectively. Antimicrobial susceptibility data of macrolide-resistant strains are presented in Table 2 . One erm(B)-positive strain exhibited the rare iMLS B phenotype. Of note, one strain was only inhibited by 8 g/ml of telithromycin. To our knowledge, this is the first report on a telithromycin-resistant S. pneumoniae isolated in Germany. The isolate had a cMLS B phenotype and erm(B) genotype. The strain was multiply resistant with high-level resistance to erythromycin A, clindamycin, tetracycline, and penicillin G and exhibited a pneumococcal serotype 15A. Sequencing of the 23S rRNA revealed seven mutations (pneumococcal numbering): T107G, A1513T, T1514A, A1530T, T1531A, A1535G, and A1745T. Analysis of the ribosomal protein L22 showed a wild type. In the ribosomal protein L4, a T20N alteration was found. Further analysis of the isolate by MLST classified the strain as belonging to sequence type (ST) 63.
The present study documented a significant increase of macrolide resistance in mainly noninvasive pneumococcal infections in adults, which parallels the increase of resistance in invasive disease in Germany (10, 17) . The rate of erythromycin A resistance in pneumococci reported by this study is significantly higher than those observed earlier (9.2%) by our work-ing group (13) . Reports on telithromycin resistance in S. pneumoniae are very scarce. Farrell and Felmingham recently reported on only 10 isolates to be telithromycin resistant among a worldwide collection of 13,874 S. pneumoniae isolates isolated between 1999 and 2003. The strains isolated in France, Italy, Spain, Hungary, and Japan had telithromycin MICs of 4 to 8 g/ml, and, as for the German isolate described in the present report, all stains showed an erm(B) genotype (4). Interestingly, further screening of the German isolate revealed additional potential resistance mechanisms, contributing to telithromycin resistance. In addition to the erm(B) resistance determinant, the strain possessed an L4 (S20N) alteration. The S20N L4 alteration has been shown to contribute to the increase of macrolide MICs in pneumococci. This observation was first made in one clinical serotype 18F pneumococcal strain isolated in 1988 in France from a blood culture (2, 4) .
In a recent report by our study group on ribosomal mutations conferring resistance to macrolides in S. pneumoniae strains isolated in Germany, only two isolates were found to carry this rare L4 alteration in combination with several 23S rRNA mutations (14) . One isolate in that report also showed an elevated telithromycin MIC of 0.25 g/ml. In addition, one pneumococcal strain (Bsp11524) isolated from the eye of a 1-year-old boy in Canada that was never treated with ketolides or even macrolides showed high-level telithromycin resistance (MIC, Ͼ256 g/ml). This strain contained a mutation in L4 (69GTG71 changed to 69TPS71) in combination with an erm(B) determinant (16) . Thus, it may be assumed that the synergy of these two mechanisms leads to ketolide resistance.
In the present study, serotyping and MLST established the telithromycin-resistant isolate 1602 to belong to the serotype 15A and ST 63. Serotype 15A isolates are extremely rare among macrolide-resistant pneumococcal strains. A study on the molecular epidemiology of macrolide resistance in Europe reports on only one such isolate among a collection of 82 a Breakpoints (intermediate, resistant) according to NCCLS: penicillin G, 0.1 to 1 g/ml, Ն2 g/ml; ampicillin, 4 g/ml, Ն8 g/ml; cefotaxime, 1 g/ml, Ն2 g/ml; erythromycin A, 0.5 g/ml, Ն1 g/ml; clindamycin, 0.5 g/ml, Ն 1 g/ml; telithromycin, 2 g/ml, Ն4 g/ml; quinupristin-dalfopristin, 2 g/ml, Ն4 g/ml; levofloxacin, 4 g/ml, Ն8 g/ml; trimethoprim-sulfamethoxazole, 1/19 to 2/38 g/ml, Ն4/76 g/ml; tetracycline, 4 g/ml, Ն8 g/ml.
b The MIC breakpoints of telithromycin were defined according to the NCCLS (susceptible, Յ1 g/ml; resistant, Ն4 g/ml). The European Agency for the Evaluation of Medicinal Products breakpoints are the following: susceptible, Յ0.5 g/ml; resistant, Ͼ2 g/ml. Due to the lack of strains exhibiting a telithromycin MIC of 1 to 4 g/ml in the present investigation, usage of the European breakpoints would not result in changes of percentage of intermediate and resistant strains presented in the table. Q-D, quinupristin-dalfopristin; SXT, trimethoprim-sulfamethoxazole. a Breakpoints are according to NCCLS (see Table 1 footnotes). Q-D, quinupristin-dalfopristin; SXT, trimethoprim/sulfamethoxazole. b One isolate was erm(B) positive in repeated assays and showed an inducible (iMLS B ) phenotype. c The MIC distribution for mef(A)-positive strains was as follows: Յ 0.016 g/ml (n ϭ 2), 0.03 g/ml (n ϭ 2); 0.06 g/ml (n ϭ 8); 0.125 g/ml (n ϭ 10); 0.25 g/ml (n ϭ 37), 0.5 g/ml (n ϭ 6).
S. pneumoniae, mef(A)
d The MIC distribution for erm(B)-positive strains was as follows: Յ 0.016 g/ml (n ϭ 9), 0.03 g/ml (n ϭ 12); 0.06 g/ml (n ϭ 2); 0.125 g/ml (n ϭ 2); 0.25 g/ml (n ϭ 1), 0.5 g/ml (n ϭ 1), 8 g/ml (n ϭ 1).
strains (12) . Clinical characteristics of the telithromycin-resistant isolate and the isolates of the same clone as available in the MLST (www.mlst.net) database and are presented in Table  3 . Isolates of ST 63 were first described in Sweden (Sweden 15A -1 clone) in the early 1990s and have thereafter been isolated from meningitis and nasopharyngeal carriage in southern European countries. It is, therefore, worth mentioning that this clone may have the potential for further global spread.
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